- Active not recruitingPHASE1, PHASE2
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
This study looks at new drug combinations for metastatic triple-negative breast cancer. It combines standard treatment with new medicines (like Durvalumab) to see if they're safe and work well together for patients whose cancer has spread.
For: Triple Negative Breast NeoplasmsUnited States · Canada · Poland - RecruitingPHASE2
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
This study looks at new drug combinations before and after surgery for early-stage lung cancer. It aims to see if these treatments are safe and work well to help people with non-small cell lung cancer.
For: Non-small Cell Lung CancerUnited States · Belgium · Canada - Active not recruitingPHASE2
Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:
This study is for women with a certain type of breast cancer (Luminal B). It tests new ways to combine chemotherapy, radiation, and new drugs (durvalumab and oleclumab) before surgery to see if they work better at treating the cancer.
For: Luminal BBelgium · France - Active not recruitingPHASE3
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
This study is for people with a type of lung cancer that can't be removed by surgery. It tests new drug combinations (Durvalumab with Oleclumab, or Durvalumab with Monalizumab) after standard treatment to see if they can help stop the cancer from coming back or getting worse.
For: Non-Small Cell Lung CancerUnited States · Australia · Brazil - Active not recruitingPHASE1, PHASE2
COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC
This study is for people with advanced bowel cancer that has spread (metastatic) and is 'microsatellite stable' (MSS). It tests new drug combinations with standard treatment (FOLFOX and bevacizumab) to see if they are safe and work well as a first treatment option.
For: Metastatic Microsatellite-stable Colorectal CancerUnited States · Australia · Canada